Close monitoring of initial enzyme replacement therapy in a patient with childhood-onset Pompe disease

Brain and Development

Volumn 34, Issue 2, 2012, Pages 98-102

  Ishigaki, Keiko ^a   Murakami, Terumi ^a   Nakanishi, Toshio ^a   Oda, Eri ^a   Sato, Takatoshi ^a   Osawa, Makiko ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE;

ANTIBODY PRODUCTION; ARTICLE; CASE REPORT; CHILD; CHILDHOOD DISEASE; CHRONIC DIARRHEA; CLIMBING; COMPUTER ASSISTED TOMOGRAPHY; CREATINE KINASE BLOOD LEVEL; DETERIORATION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ENZYME REPLACEMENT; GAIT; GLYCOGEN STORAGE DISEASE TYPE 2; GRIP STRENGTH; HEART VENTRICLE HYPERTROPHY; HUMAN; INCONTINENCE; LETHARGY; MALE; MOTOR PERFORMANCE; OXYGEN SATURATION; RESPIRATORY FUNCTION; SCHOOL CHILD; SCORING SYSTEM; SLEEP; VITAL CAPACITY; WALKING;

CHILD; CREATINE KINASE; ENZYME REPLACEMENT THERAPY; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; LONGITUDINAL STUDIES; MALE; MONITORING, PHYSIOLOGIC; TREATMENT OUTCOME; WALKING;

EID: 84855593130     PISSN: 03877604     EISSN: 18727131     Source Type: Journal    
DOI: 10.1016/j.braindev.2011.05.004     Document Type: Article

References (15)

1. Engel A.G., Hiyrschhorn R., Huie M.L. Acid maltase deficiency. Myology 2003, 1559-1586. McGraw-Hill, New York. A. Engel, C. Franzini-Armstrong (Eds.).
2. Winkel L.P., Hagemans M.L., van Doorn P.A., Loonen M.C., Hop W.J., Reuser A.J., et al. The natural course of non-classic Pompe's disease; a review of 225 published cases. J. Neurol. 2005, 252:875-884.
3. Wokke J.H., Escolar D.M., Pestronk A., Jaffe K.M., Carter G.T., van den Berg L.H., et al. Clinical features of late-onset Pompe disease: a prospective cohort study. Muscle Nerve 2008, 38:1236-1245.
4. Schoser B., Hill V., Raben N. Therapeutic approaches in glycogen storage disease type II/Pompe Disease. Neurotherapeutics 2008, 5:569-578.
5. Beck M. Alglucosidase alfa: Long term use in the treatment of patients with Pompe disease. Ther. Clin. Risk Manag. 2009, 5:767-772.
6. Amalfitano A., Bengur A.R., Morse R.P., Majure J.M., Case L.E., Veerling D.L., et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet. Med. 2001, 3:132-138.
7. Kishnani P.S., Corzo D., Nicolino M., Byrne B., Mandel H., Hwu W.L., et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007, 68:99-109.
8. Winkel L.P., Van den Hout J.M., Kamphoven J.H., Disseldorp J.A., Remmerswaal M., Arts W.F., et al. Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up. Ann. Neurol. 2004, 55:495-502.
9. van Capelle C.I., Winkel L.P., Hagemans M.L., Shapira S.K., Arts W.F., van Doorn P.A., et al. Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease. Neuromuscul. Disord. 2008, 18:447-452.
10. Strothotte S., Strigl-Pill N., Grunert B., Kornblum C., Eger K., Wessig C., et al. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J. Neurol. 2010, 257:91-97.
11. doi: (Ministry of education, culture, sports, science and technology-Japan, Motor fitness of students in 2009, in Japanese) (accessed, April 1, 2011). http://www.mext.go.jp.
12. Geiger R., Strasak A., Treml B., Gasser K., Kleinsasser A., Fischer V., et al. Six-minute walk test in children and adolescents. J. Pediatr. 2007, 150:395-399.
13. Beenakker E.A., Maurits N.M., Fock J.M., Brouwer O.F., van der Hoeven J.H. Functional ability and muscle force in healthy children and ambulant Duchenne muscular dystrophy patients. Eur. J. Paediatr. Neurol. 2005, 9:387-393.
14. Ishigaki K., Mitsuhashi S., Kuwatsuru R., Murakami T., Shishikura K., Suzuki H., et al. High-density areas on muscle CT in childhood-onset Pompe disease are caused by excess calcium accumulation. Acta Neuropathol. 2010, 120:537-543.
15. Bernstein D.L., Bialer M.G., Mehta L., Desnick R.J. Pompe disease: Dramatic improvement in gastrointestinal function following enzyme replacement therapy. A report of three later-onset patients. Mol. Genet. Metab. 2010, 101:130-133.